|
Chapman JW, Costantino JP, Dong B, Margolese RG, Pritchard KI, Shepherd LE, Gelmon KA, Wolmark N, Pollak MN. Octreotide LAR and tamoxifen versus tamoxifen in phase III randomize early breast cancer trials: NCIC CTG MA.14 and NSABP B-29.听Breast Cancer Res and Treat 153:听353-60,听2015. |
|
|
Azoulay L, Eberg M, Benayoun S, Pollak M. 5伪-Reductase Inhibitors and the Risk of Cancer-Related Mortality in Men With Prostate Cancer. JAMA Oncol听1: 314-20, 2015. |
|
|
Stolzenberg-Solomon RZ, Newton CC, Silverman DT, Pollak M, Nogueira LM, Weinstein SJ, Albanes D, M盲nnist枚 S, Jacobs EJ. Circulating Leptin and Risk of Pancreatic Cancer: A Pooled Analysis From 3 Cohorts. Am J Epidemiol听182: 187-97, 2015. |
|
|
Houghton LC, Pollak MN, Tao Y, Tu YG, Black A, Bradwin G, Hoover RN, Troisi R. Similarity of Serum and Plasma Insulin-like Growth Factor Concentrations. Biomark Cancer. 2015 Jun 8:听eCollection 2015. |
|
|
Catsburg C, Gunter MJ, Tinker L, Chlebowski RT, Pollak听惭, Strickler HD, Cote ML, Page DL, Rohan TE. Serum IGFBP-2 and Risk of Atypical Hyperplasia of the Breast. J Cancer Epidemiol听2015, 2015. |
|
|
Mu F, Hankinson SE, Schernhammer E, Pollak MN, Missmer SA. A Prospective Study of Insulin-Like Growth Factor 1, Its Binding Protein 3, and Risk of Endometriosis. Am J Epidemiol听182: 148-56, 2015. |
|
|
Kordes S, Pollak MN, Zwinderman AH, Math么t RA, Weterman MJ, Beeker A, Punt CJ, Richel DJ, Wilmink JW. Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trial. Lancet Oncol听16: 839-47, 2015. [see also favorable editorial comment [.pdf] - Lancet: 2015] |
|
|
Blouin MJ, Bazile M, Birman E, Zakikhani M, Florianova L, Aleynikova O, Powell DR, Pollak M. Germ line knockout of IGFBP-3 reveals influences of the gene on mammary gland neoplasia. Breast Cancer Res Treat听149: 577-85, 2015. |
|
|
Morita M, Gravel SP, Hulea L, Larsson O, Pollak M, St-Pierre J, Topisirovic I. mTOR coordinates protein synthesis, mitochondrial activity and proliferation. Cell Cycle听14: 473-80, 2015. |
|
|
Cifarelli V, Lashinger LM, Devlin KL, Dunlap SM, Huang J, Kaaks R, Pollak MN, Hursting SD. Metformin and rapamycin reduce pancreatic cancer growth in obese prediabetic mice by distinct microRNA-regulated mechanisms. 顿颈补产别迟别蝉听64: 1632-42, 2015. |
|
|
Joerger M, van Schaik RH, Becker ML, Hayoz S, Pollak M, Cathomas R, Winterhalder R, Gillessen S, Rothermundt C. Multidrug and toxin extrusion 1 and human organic cation transporter 1 polymorphisms in patients with castration-resistant prostate cancer receiving metformin (SAKK 08/09). Prostate Cancer Prostatic Dis听18: 167-72, 2015. |
|
|
Cao Y, Nimptsch K, Shui IM, Platz EA, Wu K, Pollak MN, Kenfield SA, Stampfer MJ, Giovannucci EL. Prediagnostic plasma IGFBP-1, IGF-1 and risk of prostate cancer. Int J Cancer听136; 2418-26, 2015. |
|
|
Assayag J, Pollak MN, Azoulay L. The Use of Aspirin and the Risk of Mortality in Patients with Prostate Cancer. J Urol听193: 1220-5, 2015. |
|
|
Inamura K, Song M, Jung S, Nishihara R, Yamauchi M, Lochhead P, Qian ZR, Kim SA, Mima K, Sukawa Y, Masuda A, Imamura Y, Zhang X, Pollak MN, Mantzoros CS, Harris CC, Giovannucci E, Fuchs CS, Cho E, Chan AT, Wu K, Ogino S. Prediagnosis Plasma Adiponectin in Relation to Colorectal Cancer Risk According to KRAS Mutation Status. J Natl Cancer Inst: in press, 2015.听 |
|
|
Allen DB, Backeljauw P, Bidlingmaier M, Biller B, Boguszewski M, Burman P, Butler G, Chihara K, Christiansen JS, Cianfarani S, Clayton PE, Clemmons D, Cohen P, Darendeliler F, Deal C, Dunger DP, Erfurth EM, Fuqua J, Grimberg A, Haymond M, Higham C, Ho KK, Hoffman AR, Hokken-Koelega AC, Johannsson G, Juul A, Kopchick JJ, Lee P, Pollak M, Radovick S, Robison L, Rosenfeld R, Ross RJ, Savendahl L, Saenger P, Toft Sorensen H, Stochholm K, Strasburger CJ, Swerdlow A, Thorner MO. Growth Hormone Safety Workshop Position Paper: a critical appraisal of recombinant human growth hormone therapy in children and adults. Eur J Endocrinol.174(2):P1-9,听2015.听 |
|
听